INTRODUCTION
It has been described (1, 2) how organ alloengraftment occurs as the result of "responses of co-existing donor, that is, passenger leukocytes, and recipient immune cells, each to the other, causing reciprocal clonal expansion followed by periph-eral clonal exhaustion" (3, 4) . The persistence in the host of donor passenger leukocytes above some threshold required to maintain the clonal exhaustion-deletion induced acutely by the migratory donor cells is a necessary condition for long organ allograft survival (1) (2) (3) (4) (5) . The variable deletional tolerance of the double-immune response evolves spontaneously in some experimental models (6) (7) (8) (9) , especially when the transplanted organ is the liver (6, 7, 10, 11) . Immunosuppression usually is required to prevent one immune cell population from destroying the other before the reciprocal deletion can occur.
This paradigm has been controversial (12) (13) (14) (15) , in part because it is incompatible with numerous competing hypotheses of organ engraftment (1, 2) . For example-, the migratory donor cells found in recipient tissues early and late after organ transplantation include major histocompatibility complex (MHC) class II'" dendritic cells (DC) (3-5, 11, 16-18) that have been associated historically with protective immunity (that is, rejection) rather than immune nonreactivity or tolerance (19) (20) (21) (22) . We studied the donor MHC class II+ cells in a rat liver transplant model in which donor-specific tolerance develops over a period of 1 month under an umbrella of tacrolimus (TAC) immunosuppression. In addition to serial donor leukocyte determinations in the liver allograft and host spleen during the 4-week period of tolerogenesis, cytokine and other parameters that reflect the rise and decline of immune activation were analyzed in the same locations. When appropriate, the findings were compared with those after transplantation ofthe less tolerogenic heart under identical treatment conditions. The results undermine the widely held view that the expression (or nonexpression) of MHC class II of the migratory donor leukocytes is a crucial determinant of outcome after organ transplantation.
MATERIALS AND METHODS

Animals and Transplantation Procedures
Male Lewis (LEW, RT11) and Brown Norway (EN, RTl n) rats weighing 150-250 g (Harlan Sprague Dawley, Indianapolis, IN) were maintained in a specific pathogen-free environment at the University of Pittsburgh and used as donors and recipients, respectively. Heterotopic abdominal heart transplantation (HTx) and orthotopic liver transplantation (OLTx) (portal revascularization only) were carried out as previously described (5) 
Immunosuppression
The naive BN heart and liver recipients were administered TAC (FK 506, Fujisawa Pharmaceutical Co., Osaka, Japan) at a daily intramuscular (lM) dose of 1.0 mg/kg on days 0-13, with single supplemental injections of the same dose on days 20 and 27.
Experimental Design
Cohorts of recipients were killed and autopsied on posttransplant days 1, 3, 5, 7, 14, and 28. The allograft and the host spleen were sectioned and fixed in 10% neutral-buffered formalin for routine histopathology, embedded in optimum cold temperature compound (Tissue-Tek, Ames Division, Miles Laboratories, Inc., Elkhart, IN) for immunohistochemical studies, and snap-frozen in liquid nitrogen for mRNA extraction. In addition, recipient spleen was used for flow cytometry. Several heart and liver recipients were kept for 100 days and killed for histopathological analysis of chronic rejection (CR) in the allografts and for collection of cervical lymph nodes for mixed lymphocyte reaction (MLR) assays.
Routine Histopathology of Allografts
Formalin-fixed heart and liver allografts were embedded in paraffin, sectioned at 4 J1.ill, and stained with hematoxylin-eosin. In heart allografts, the overall severity of inflammation in the endocardium, pericardium, interstitium, and periarterial spaces was semiquantitatively graded on the scale of 0-4 as none, minimal, mild, moderate, or severe (23) . Arterial alterations, including the presence of inflammation, edema, fibrosis, and vacuolation of the intima, media and adventitia were graded in the same way. In addition, the total number of arteries more than 80 J1.ill present in cross-section was recorded to assure a similar sampling between animals and graded for obliterative arteriopathy (OA).
Histopathological changes in the liver allografts were evaluated as the presence of bile duct damage and/or loss, bile ductular proliferation, the presence of subendothelial mononuclear infiltration in the portal or central veins, and severity of portal tract inflammation.
I mmunohistopathological Analyses
Portions of allograft and recipient spleen were sectioned at 4 !J.m and stained with a routine indirect avidin-biotin complex method or immunofluorescence technique (24) . Biotinylated or Cy3-conjugated monoclonal antibody (mAb) L21-6 (mouse IgGl)' which reacts with the class II MHC antigens of LEW (donor) but not BN (recipient) (25) , was used to detect donor MHC class II+ cells. The number of L21-6+ donor cells was counted in 20 randomly selected high power fields (HPF; x 400 magnification). Isotype-matched nonspecific antibody was substituted for mAb L21-6 in negative controls.
Other mAbs used in this study included R7.3 (a(3TCR), EDI (infiltrative macrophages), ED2 (tissue macrophages), anti-rat IgM (B cells), OX33 (CD45RA, B cells), OX8 (CD8a), and 8A2 (CDllc, DC). Most of these lineage-specific mAbs were conjugated with fluorescein (PharMingen, San Diego, CA and Serotec, Kidlington, Oxford, UK). For unconjugated mAb, fluorescein-conjugated goat anti-mouse IgG was used as a secondary antibody.
Cell Proliferation and Apoptosis
Animals were given an intravenous (IV) injection of 50 mg/kg 5-bromo-2'-deoxyuridine (BrdU, Sigma, St. Louis, MOll hour before death. The labeled cells were detected with an anti-BrdU mAb (Amersham Life Science Inc., Cleveland, OH) using routine indirect immunoperoxidase staining. The number oflymphocytes undergoing DNA synthesis (in S-phaseJ was determined by counting the number of BrdU+ lymphocytes in 20 randomly selected HPF (x 400).
The terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick end labeling ITUNELJ method using Apop Tag kit rIntergen, Purchase, NY) localized apoptotic cells in the same paraffin blocks used for the BrdU DNA synthesis detection. Positively stained cells were counted in 20 randomly selected HPF (see above).
Flow Cytometry
Splenocytes were prepared by mincing a piece of spleen and lysing the red blood cells. Splenocytes were analyzed by two-color flow cytometry using affinity purified biotinylated mAbs 163 (rat IgG2b) and 42 (rat IgG2a), specific for the RT1.A 1 (LEW MHC class I antigen) and the RT1.An (EN MHC class I antigen), respectively (26) . Cychrome-conjugated streptavidin (PharMingen) was applied as a secondary antibody. Lineage-specific fluorescein-conjugated mAbs (see above) were used for double stain.
RNA Preparation and RNase Protection Assay (RPA)
Total RNA was extracted from frozen samples by using TRIZOL Reagent (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. The concentration of RNA was determined by UV spectrophotometer at 260 nm. An RNase protection assay (RPA) using commercially available kits (PharMingen) was used to quantify cytokine mRNA production. Radiolabeled antisense RNA multiple probes were synthesized using in Vitro Transcription Kit and rat cytokine multiprobe template sets (rCK-1 and rAPO-I, PharMingen), which included probes for cytokines [interleukin (IL)-la, IL-ll3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-IO, tumor necrosis factor (TNF)-a, TNF-I3, and interferon (IFN)'Y]' apoptosis-associated molecules (Fas, FasL, caspase-1, 2, 3, bel-X, bcl-2, and bax), respectively, and housekeeping genes (L32 and GAPDH).
32P-Iabeled probes (8.0x 10 5 cpm) and sample RNA (5 J.Lg) were hybridized at 56°C for 12-16 hours and single-stranded RNAs including antisense RNA probes were digested by using RPA Kit (PharMingen). The protected RNA duplexe~were isolated by RNase inactivation/precipitation solution (Ambion Inc., Austin, TX), and electrophoresed in a standard sequencing gel. Dried gels were exposed to Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CAl for 12 hours at room temperature. The radioactivity of each band was measured by l3-scan (PhosphorImager, Molecular Dynamics) and NIH Image analysis software. The results were normalized to GAPDH and expressed as a ratio of cytokine or apoptotic signallGAPDH.
Mixed Lymphocyte Reaction
One-way MLR assayed antidonor reactivity of BN recipients, in vitro (5). Responder cervical lymph node lymphocytes (1.75 x 10 5 ) obtained from BN recipients 100 days after HTx or OLTx and irradiated (2000 rad) stimulator cells (3X10 5 ) were combined in a final volume of 0.2 mL RPM! supplemented with 25 mM HEPES buffer, 5X 10-5 M 2-mercaptoethanol, 2 mM L-glutamme, 50 D/ml penicillin, 50 J.Lg/ml streptomycin, ~-monomethyl-L-arginine-HOAc (Cycloapss Biochemical Co., Slake Lake, UT) and 10% heat-inactivated normal rat serum. Triplicate cultures were incubated in a humidified atmosphere of 5% CO2 in air for 5 days at 37°C. One J.LCi of 3H-thymidine was added to each well 16 hours before the termination of the culture. Cultures were harvested with multiple sample harvester and 3H-thymidine uptake was determined by liquid scintillation.
Statistical Analysis
All results were expressed as mean::!:SD. Numbers of positively stained cells in tissue sections and mRN A levels in RP A assays were analyzed by one-way factorial analysis of variance. Fisher's PLSD test assessed the statistical difference between groups. Student's t test was used for the analyses of MLR P less than 0.05 was considered significant.
RESULTS
Untreated BN recipients reject LEW heart allografts in 8 days and LEW livers in 23-32 days (median 28.5), although all liver and heart grafts survive for 100 days under the 28-day course ofTAC. As reported previously (5), however, by 100 days (73 days after the last dose of TAC), the liver allografts were CR free ( Fig. 1, right) although the transplanted hearts had severe CR (Fig. 1, left) . CR was manifested by endocardial, pericardial, interstititial, and periarterial mononuclear inflammation, and by patchy interstitial fibrosis. The overall inflammation score (23) was 2.8=1.1. In addition, OA was recorded in 53.2% of the vessels examined. The liver allografts at day 100 were essentially normal, except for mild lymphocytic infiltrates in the portal triad and occasional bile duct proliferation indicative of minor biliary complications, presumably related to the lack of an arterial blood supply (Fig. 1, right) .
The histopathological findings at 100 days posttransplantation were congruent with the results of MLR studies at the time of death. Antidonor proliferation of cervical lymph node lymphocytes of OLTx recipients was significantly depressed (P<O.OOl), although the response of comparable cells from 100-day heart recipients was much less reduced (P=O.068) (Fig. 2) . Reactivity against third party strain cells CAC!) was fully preserved in both liver and heart recipients.
Serial Cytokine mRNA Levels
Previous studies of this liver transplant model demonstrated that the evolution ofTAC-assisted donor-specific tolerance is complete by 4 weeks after which the liver allograft remains CR-free without immunosuppression (5, 17) . Cytokine profiles were monitored during the 28-day period of the immunosuppression. The results were compared with those after transplantation under identical treatment of the less tolerogenic (that is, CR-prone) heart allografts.
Levels in the allografts. When no immunosuppression was given, IL-2 and IFN'Y were progressively up-regulated in both the liver and heart allografts during the first 7 posttransHeart Graft (dayl 00) 
Groups
Heart Recipients FIGURE 2. One-way MLR. One hundred days after LEW to BN heart and liver transplantation under a 28-day course TAC immunosuppression, recipient cervical lymph node lymphocytes were stimulated in MLR with irradiated (20 Gy) LEW (donor), BN (syngenic), and ACI (third party) lymphocytes, using cell·free medium as background con· trol. The LEW-specific proliferative response shown in the third bars of each cluster can be compared with the AeIspecific (that is, third party) response in the fourth bars. Bars 1 and 2 are cell-free medium and syngeneic (EN) stimulator controls. Donor-specific responsiveness was reduced significantly in the liver (P<O.OOl vs. normal BN), but inconclusively in the heart recipients (P=0.068).
Liver Graft (daylOO) FIGURE 1. Routine histopathology of LEW heart (left) and liver (right) allografts 100 days after transplantation to BN recipients under a 28-day course TAC immunosuppression. The liver allograft at day 100 is essentially normal and the heart allograft has severe CR, including inflammatory infiltrates, patchy fibrosis, and obliterative arteriopathy.
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Vol. 74, No.1 plant days, significantly more so in the hearts (Fig. 3, top) . Smaller increases of 1L-4 and IL-10 were also observed. The short course of TAC altered the mixed TH1-TH2 response, mainly by down-regulation of signals for IL-2 and IFN y that was significantly more pronounced in the liver allografts. In addition, a significantly greater increase in mRNA for 1L-10 was observed in the TAC-protected liver allografts than in the comparable heart allografts (Fig. 3,  bottom) .
Levels in host spleens. In untreated liver recipients, and to a significantly lesser extent in unmodified heart recipients, both TH1 (1L-2, 1FNy) and TH2 (1L-4, IL-10) cytokine expression in the recipient spleens was increased. The directional changes were similar to those that occurred in both kinds of organ allografts (compare the top of Fig. 4 with the top of Fig.  3 ).
TAC treatment resulted in down-regulation in the host spleen of 1L-2 and IFNI' mRNA, significantly more in liver than in heart recipients (Fig. 4, bottom) . The tripling or quadrupling of the TH2 cytokine increases in the spleen (IL-4 and IL-10) were not different under TAC than in animals that were not treated. Of interest, the preferential up-regulation ofIL-10 observed in the liver allografts ofTAC-treated recipients was not seen in the spleens of these recipients (compare bottom of Figs. 3 and 4) .
Proliferation / Apoptosis
In the allografts. In untreated recipients, proliferating leukocytes (detected by BrdU staining) increased progressively in hearts and livers during the first posttransplantation week (Fig. 5A, top) . The proliferation was strongly associated with apoptosis (that is, TUNEL + cells) (Fig. 5B, top) . However, the apoptotic cells were only one-third to one-half as frequent as the BrdU+ cells (compare Fig. 5A and B, taking into account the different scales).
Under TAC, the frequency of the BrdU+ leukocytes rose initially, but declined and then remained above baseline out ''''''' FIGURE 3. Serial mRNA for cytokines in the allografts: heart (open bars) and liver (black bars) (n=3-6 at each time point). *P<O.05 (liver vs. heart). N, Normal heart and liver. Upper panels, Without immunosuppression, there was dramatic up· regulation of THI cytokines (IL-2, IFNl') in both kinds of allografts. There also were modest increases (from undetect· able) of the TH2 cytokines, IL-4 and IL·IO. Lower panels, Under TAC treatment, the THl cytokines were down.regulated, much more in liver than the heart allografts. TH2 cy· tokine changes associated with therapy were limited to up· regulation of IL·IO in the liver allografts. to 28 days (Fig. 5A, bottom) . In the heart allografts, these cells were mainly in lymphocyte aggregates in the epicardium, pericardium, and periarterial areas. The number of TUNEL + (apoptotic) cells increased in rough parallel to the BrdU+ cells and at two time points (days 1 and 14) , the apoptotic cells were significantly more numerous in liver than in heart grafts (Fig. 5B, bottom) . With or without immunosuppression, mRNA for Fas and caspase-3 were significantly more up-regulated in liver than in heart allografts at most time points (Fig. 6) .
In host spleens. At day 5 in untreated OLTx recipients, the BrdU+ cells rose in the recipient spleens to a peak of 365±28.4 cellslHPF, more than twice the number in the spleens of the heart recipients ( Fig. 7 A, top) . After both liver and heart transplantation, the BrdU+ cellslHPF were 5 to 10 times more numerous in the host spleen than the respective allografts [compare Fig. 7 A, top (spleen), with Fig. 5A, top  (allograft) ].
Under TAC therapy, the burst of BrdU+ cells in the host spleen after liver as well as heart transplantation was blunted or reversible. The number of positive cells remained elevated throughout the 28 days of immunosuppression (Fig.  7 A, bottom) . In parallel with the BrdU+ leukocytes, a smaller number of TUNEL + (apoptotic) cells were observed in the host spleen after both kinds of transplantations, similar to the BrdU+ !I'UNEL + proportions in the allografts (compare Fig. 7B , bottom, with Fig. 5B, bottom) . The apoptotic cells in both the host spleen (Fig. 7B, bottom) and the transplanted organ (Fig. 5B, bottom) was greater when the allograft was a liver (significant on days 1 and 14). This observation was supported by the RPA ofmRNA for apoptosis-associated molecules that showed greater up-regulation of apoptotic signals in the spleens of TAC-treated liver recipients (Fig. 8) . The latter confirmatory evidence was weakened by the limitation of this finding to day 14.
Immunohistopathological Studies of Host Spleen
Donor MHC class Ir (L21-6+) cells. After HTx, less than 0.25 donor MHC class II+ cellslHPF were detected in the red pulp, peri arteriolar lymphoid sheath (PALS), and marginal zone of the spleen, regardless of TAC administration (data not shown). In contrast, many more donor MHC class II+ cells were found in the recipient spleen after liver transplantation. At 1 and 3 days, the number and location of these cells was the same with or without TAC treatment. Donor class II+ cells disappeared from the spleen of untreated animals by 7 days. In TAC-treated liver recipients (Fig. 9) , the mean numbers of donor MHC class II+ cells were 13.0, 11.8, 1.7, and 1.1 cellslHPF at 1, 3, 7, and 14 posttransplant days, respectively. The donor MHC class II+ cells localized predominantly to the periphery of the splenic PALS and marginal zone by 1 day after transplantation although a small number was also found within the PALS. Donor MHC class II+ cells disap- (Fig. 10, A and B) . Double staining for macrophages (ED1, ED2) excluded the possibility of significant donor macrophage migration to the recipient spleen (Fig. 10, C and D) . The few donor MHC class II+ cells localizing to T cell areas (mAb R7.3+, a,BTCR+) (Fig. 10 , E and F) were also positive for CDllc (8A2), indicative of donor MHC class II+ DC (Fig. 10, G and H) . Although expression of CD8a correlates with differences in lineage origin and function activity of DC (27) , only a few donor DC expressed CD8a. This suggests that donor DC migrating into the recipient spleen after OLTx are a mixture of "myeloid" and "lymphoid" DC (Fig. 1OI) .
Flow Cytometry of Spleen Cells
Because the foregoing studies were limited to donor MHC class II+ cells, they grossly underestimated the total donor cell load delivered to the spleen. To obtain a rough estimate of the true migratory leukocyte traffic relative to the MHC class II+ subset, spleen cell suspensions were analyzed by flow cytometry using antidonor/recipient MHC class I mAbs after both HTx and OLTx. With or without treatment, donor cells could not be reliably detected by flow cytometry in the recipient spleen at any time point after HTx (data not shown).
Without TAC treatment, donor cells disappeared from the spleens ofliver recipients by 7 days. Under TAC, donor MHC class 1+ cells accounted for 1 to 5% of splenocytes between 1 to 14 days after OLTx (Fig. 11) . The donor cells at 7 days in the treated animals were mainly a!3TCR+ (50-70%), but NK and B cells also were identified. DISCUSSION It is known that donor passenger leukocytes leave the allograft after organ transplantation (28) (29) (30) and migrate preferentially at first to host lymphoid organs (17, 24, 31, 32) . They induce an adaptive immune response that may proceed to variable degrees of apoptosis-associated (33) clonal exhaustion-deletion (1-4, 34) , the maintenance of which is dependent on the continued presence of the mobile donor cells (1, 2) . Survival of small numbers of these donor passenger leukocytes is facilitated by their secondary migration to "protected" nonlymphoid sites including the organ allograft (35) (36) (37) , from where they may pass back to host lymphoid organs and maintain the donor-specific clonal exhaustion-deletion induced at the outset (1, 2) .
In this paradigm, the key event in determining immune responsiveness or nonresponsiveness to an organ is leukocyte migration and localization. Consequently, the variable posttransplant events are best understood in terms of dose and localization of the mobile antigen, and particularly the time during which this alloantigen is in host lymphoid organs (1, 2) . The serial changes in proliferationiapoptosis indices in our experiments suggest that the immune activation-dependent mechanisms that result in the evolution of variable levels of immunosuppression-assisted deletional tolerance and engraftment differ only in degree after liver and heart transplantation. The proliferation response induced by the highly tolerogenic liver exceeded that induced by the weakly tolerogenic heart. The differences in outcome were explicable by the far greater load of immunostimulatory passenger leukocytes contained in hepatic allografts, and by the persistence of more of these cells in the liver recipients.
In this interpretation, the changing cytokine profiles observed were downstream effects of unmodified or immunosuppression-altered immune activation, rather than implying any self-sustaining immunoregulatory role in organ engraftment of the cytokines per se, singly or in combination. One of the immune regulation hypotheses holds that the absence of the TH1 type cytokines CIL-2 and IFN')') and the presence of TH2 type cytokines (IL-4 and IL-10) lead to the CR-free organ transplant acceptance (38) (39) (40) . This has not been supported by molecular studies of cytokine mRNA of human renal allografts or by observations in several animal models (41) . We have suggested instead that alloengraftment is an active process whose perpetuation requires the persistence of donor leukocytes (1,2).
Our specific question was whether there was any histopathological evidence in the host spleen suggesting a unique role of particular lineages of the donor leukocytes, either in eliciting rejection or inducing tolerance. The question was prompted in part by the results of a recent study by Ichikawa et a1. (35) in which the percentages and lineages of donor leukocytes in cell suspensions prepared from test LEW heart allografts and host spleens were determined after their transplantation to drug-free BN recipients who had variably tolerized 100 days previously by LEW heart, bone marrow cell, or liver transplantation under the standard 28-day course of TAC. In these earlier studies, flow cytometry analyses and parallel histopathological-immunocytochemical findings showed that the failure of CR to develop in the challenge hearts correlated more directly with the total quantity of donor leukocytes in the challenge cardiac allografts and the spleens of the primed host than with the small subset of MHC class II+ donor leukocytes that included DC (35) .
Because MHC class II+ cells function as antigen presenting cells (APC) and because DC can prime T cells in vitro, it has been assumed that DC constitute the truly immunogenic subset of passenger leukocytes (19) (20) (21) 42 ). Neither our findings in the spleens of recipients of primary liver allografts nor the related observations of Ichikawa et al. (35) formally eliminate the possibility that donor DC playa crucial role in graft outcome. Our data are not consistent with a lineagespecific hypothesis to explain either organ rejection or alloengraftment. During the first 2 weeks after liver transplantation, donor cells accounted for 1 to 5% of the host spleen leukocytes. Most of these donor cells were class II-(that is, 50-70% were T cells). limited to the splenic PALS, in contiguity with T cells (see Fig. 10 ). Despite their strict localization to the splenic T cell area, it was not possible with our methodology to identify the aggregation of host T cells around donor DC that has been ascribed to "direct allorecognition" or "direct alloactivation." Thus, it remains unclear whether the donor MHC class II+ cells that reached splenic T-cell areas triggered host T cells directly or whether the alloantigens were presented as class II-(or class 1) derived peptide to T cells via host APC by the classical "exogenous" indirect pathway (43) that has been increasingly associated with chronic (as opposed to acute) rejection (19, 20, (44) (45) (46) .
It is widely believed that allorecognition of and direct immune activation by highly immunogenic passenger leukocytes is responsible for acute rejection (20, 42, 44, 47) . This hypothesis has been questioned by studies suggesting that acute rejection is largely, if not exclusively, by the indirect pathway (48) (49) (50) (51) . Whether and how peptide derived from the donor passenger leukocytes is captured and processed by the host APC via the indirect pathway is unclear.
Finally, the unique immunogenicity, of the passenger leukocytes has been ascribed to special qualities of DC, e.g., the expression of MHC class II or costimulatory molecules such as B7 (20, 52, 53) . We studied the possibility that passenger leukocytes are immunogenic mainly because they can migrate to lymphoid organs although parenchymal cells ostensibly lack immunogenic properties simply because they are immobile and cannot reach these lymphoid destinations (2, 35) . If this is correct, the quantity rather than the lineages of the passenger leukocytes is the key factor in initiating the immune activation that may lead to acute rejection, or proceed to clonal exhaustion-deletion and variable tolerance.
